– Sathgen Therapeutics announces dosing of the first cohort of patients with MSP008-22, a new anticancer drug
~ Promising efficacy against difficult-to-treat cancers, including triple-negative breast cancer, and enhancement of the effect of standard chemotherapy during preclinical development ~
MUMBAI, India, July 21, 2023 /PRNewswire/ — Sathgen Therapeutics, a division of Godavari Biorefineries Limited (GBL), one of India’s leading chemical conglomerates, has announced the completion of the first cohort of a Phase 1 clinical trial of its new chemical entity, MSP008-22, the first of its kind. The clinical trial program is managed by Clinexel Life Sciences, a renowned contract research organization in the healthcare industry.
Sathgen Therapeutics aims to develop MSP008-22 for difficult-to-treat cancers, starting with triple-negative breast cancer (TNBC) and prostate cancer as proof-of-principle. MSP008-22 is effective against treatment-resistant cancer cells in preclinical models, and demonstrates an excellent safety profile with no serious adverse events in the first cohort of patients.
Professor Sendurai Mani, Associate Director, Brown University Legorreta Cancer Center and Scientific Co-Founder of Sathgen Therapeutics, stated: “TNBC accounts for 30% of breast cancer-related deaths. Absence of estrogen and progesterone receptors and HER2 expression make treatment with conventional hormone therapy difficult. MSP008-22 will address this important unmet need for TNBC patients.”
Dr. Sangeeta Srivastava, CEO, GBL, and Chief Scientific Officer, Sathgen Therapeutics, said: “This clinical trial, an important milestone for us, marks the start of clinical development of our first programme. MSP008-22 is our leading candidate to treat TNBC and prostate cancer, and improves the efficacy of standard treatment chemotherapy.”
Samir Somaiya, President and Director, GBL, and Co-Executive Founder, Sathgen Therapeutics, said: “At GBL, research is the cornerstone of our business, creating continuous value for society. We are dedicated to pioneering drug discovery to deliver sustainable advantage. The trial represents a critical milestone in our mission to help patients with difficult-to-treat cancers.”
Dr Deepa Arora, CEO, Clinexel, explained: “The successful completion of the first cohort of this study (NCT05478486) in patients with advanced solid tumors without any adverse events is very encouraging. We are working to provide a safe and effective oral therapy that will benefit patients with TNBC or prostate cancer.”
Sathgen Therapeutics is focused on developing and commercializing new medicines to improve the lives of cancer patients. With more than 15 cancer candidates in development, Sathgen Therapeutics remains committed to advancing cancer therapeutics. For more information, visit the website https://sathgentherapeutics.com.
For collaboration or investment opportunities, please contact Sathgen Therapeutics at BD@sathgentherapeutics.com or InvestorRelations@sathgentherapeutics.co…. For more information, visit www.clinicaltrials.gov.
Photo: https://mma.prnewswire.com/media/2157751…Logo: https://mma.prnewswire.com/media/2157753…
View original content: https://www.prnewswire.com/news-releases/sathgen-therapeutics-anuncia-la-dosificacion-de-la-primera-cohorte-de-pacientes-con-msp008-22-301882736.html
